Obesity Clinical Trial
Official title:
An M-Health Intervention to Increase Activity Levels in Rural Veterans
MapTrek is a mobile-phone-based web app that allows participants to take a virtual walk in interesting locations around the world while tracking their progress against the progress of other veterans on an interactive map. Steps are counted using a commercially available triaxial accelerometer (e.g. Fitbit), and users see their own updated progress overlaid on Google Maps, with Google Maps features (e.g. zooming, street view, etc.) available. The objective is to report activity levels in the virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity.
All consented participants will be provided with a Fitbit and instructed to wear it all day
for the next 9 weeks. This process should take approximately 15 to 45 minutes, depending on
group assignment.
This, plus an exit survey and 3-month follow-up survey(given via text message or phone call,
whichever the participant prefers), will be the extent of the participation in the control
group.
Members of the intervention group will be instructed on how to use MapTrek, the virtual
walking race. Data collected during the first week from the Fitbit will be used to compute
baseline activity level. This baseline data will be used to place participants into an
appropriate initial race group. Participants are placed into race groups with other
individuals who are active at a similar level, so that groups will be competitive.
Each virtual walking race will begin on Monday and end on Sunday. Depending on each veteran's
performance each week, group assignment may change. Participants will compete in 8 week-long
races over the course of the study.
For each race, the participants will receive 2-4 text messages each day including a daily
status report and a link to the current race. The participants will also periodically receive
challenge text messages. If participants accept a challenge and meet it, they will be awarded
bonus steps to help move them along the route in the race.
To win a race, participants must be the first to cross the finish line on the route for the
week. There is a leaderboard within MapTrek that helps participants determine their standings
within each race. Participants are allowed to choose a screen name to show on the leaderboard
so that they may remain anonymous if desired.
For all participants, the investigators will collect first and last name and the last 4
digits of the participant's Social Security Number for consent documentation purposes and to
look the person up in the VA medical record (CPRS). The following information will be
collected from CPRS at baseline: age, sex, race, marital status, height, weight, body mass
index, blood pressure, zip code, and current medications. Height, weight, body mass index,
and blood pressure values will be collected again at the 9 week and 3 month follow ups. The
following information will be collected from the MOVE! participation records at baseline:
date enrolled in MOVE! program, number of MOVE! classes attended, weight when enrolled in the
MOVE! program.
At the end of the 9 weeks of participation, participants will be contacted to complete an
exit survey either via text message or phone call, whichever was stated as the preferred
method at enrollment. This will take approximately 10 minutes to complete.
3 months after the study ends, the participants will be contacted to complete a 3-month
follow-up survey either via text message or phone call, whichever was stated as the preferred
method at enrollment. This will take approximately 10 minutes to complete.
Participants who do not respond will be contacted via text message and phone call up to 3
times. If participants still cannot be reached they will be considered lost to followup.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |